LGG Probiotic for Respiratory Infections and Immune Support: What the Research Shows About Colds, Daycare Studies, and the Gut-Lung Axis (2026)

Search for "best probiotic for immune support" and you will find a wall of confident marketing. The honest picture from the research is more interesting and more nuanced. Lactobacillus rhamnosus GG (LGG) is the single most-studied probiotic strain in the world, and it has a real, if specific, body of evidence on respiratory infections. That evidence is strongest in one place, children in group settings, and genuinely weak or null in another, adult common colds. This article lays out exactly what the trials show, where the gut-lung connection comes from, and how to think about LGG for immune support without overpromising.

What LGG Is, and Why the Gut Has Anything to Do With the Lungs

LGG is Lactobacillus rhamnosus GG, strain ATCC 53103, isolated from the human gut in 1983. It is the reference strain for much of modern probiotic science, with hundreds of human trials behind it.

The idea that a gut bacterium could influence respiratory infections rests on the "gut-lung axis," the growing understanding that the immune education happening in the gut has systemic effects, including at distant mucosal surfaces like the airway. Probiotics in the gut can modulate immune signaling that reaches beyond the intestine.

There is mechanistic support for this with LGG specifically, though it is preclinical. In human cells, LGG-derived soluble mediators conditioned dendritic cells in a way that drove interferon-gamma-producing T cells and increased regulatory (Foxp3-positive) T-cell populations, demonstrating that LGG can shape adaptive immune responses [Ludwig 2018 PMID 30042761]. In an animal model, intranasal LGG given to mice before an influenza (H1N1) challenge improved survival, reduced symptoms, increased lung natural killer cell activity, and changed inflammatory cytokine signaling [Harata 2010 PMID 20438620].

These are mechanism studies, not proof of benefit in people. A cell-culture result and a mouse survival curve tell you a pathway is plausible. They do not tell you a capsule will keep you from catching a cold. For that, you need the human trials, and this is where the picture splits sharply by population.

The Strongest Evidence: Children in Daycare and Hospitals

The clearest respiratory benefits for LGG show up in children, particularly in group settings where infection pressure is high.

The foundational trial is Hatakka and colleagues, published in the BMJ in 2001. In 571 Finnish daycare children, LGG-containing milk produced a modest reduction in illness-related absences, roughly 16 percent fewer days, a 17 percent relative reduction in children experiencing respiratory infections with complications, and a 19 percent relative reduction in respiratory antibiotic courses [Hatakka 2001 PMID 11387176]. It is important to be precise here: the effects were modest, and several outcomes, including the headline absence reduction, did not reach statistical significance after adjustment. This is a positive but cautious result, not a slam dunk.

A stronger single result came from Hojsak and colleagues in 2010. In a randomized trial of 281 daycare children, LGG significantly reduced upper respiratory tract infections (relative risk 0.66) and respiratory infections lasting more than three days (relative risk 0.57), with no significant effect on lower respiratory tract infections [Hojsak 2010 PMID 19896252]. This is the most convincing daycare-respiratory trial for LGG specifically.

The same group also tested LGG in a hospital setting. In 742 hospitalized children, LGG significantly reduced the risk of nosocomial (hospital-acquired) respiratory tract infections (relative risk 0.38, roughly one prevented case for every 30 children treated) and respiratory infections lasting more than three days [Hojsak 2010 PMID 20403940]. Reducing infections children pick up while already in the hospital is a meaningful, practical outcome.

In the most fragile population, premature infants, the evidence is borderline. A trial in 94 preterm infants found that rhinovirus-associated respiratory infection episodes were reduced by LGG (relative risk 0.49), but this just missed statistical significance (P=0.051); the clearly significant effect in that study came from a prebiotic arm, not from LGG [Luoto 2014 PMID 24131826]. Honest reading: a trend, not a proven effect.

The Weak Spot: Adult Colds and Experimental Rhinovirus

If the pediatric daycare data is the strong side of the ledger, adult common colds are the weak side. Here, LGG has repeatedly failed to show a clear benefit.

The most rigorous tests use experimental rhinovirus challenge, where healthy adults are deliberately infected under controlled conditions. In one such trial of 59 adults, neither live nor heat-inactivated LGG significantly reduced the rate of infection or the severity of cold symptoms [Kumpu 2015 PMID 26322544]. A companion analysis found no significant difference in nasal viral loads with LGG compared with placebo, only a non-significant downward trend [Tapiovaara 2016 PMID 26990147].

Even the larger field trials in children show the limits. A 28-week study of 523 daycare children given LGG milk had a null primary outcome in the full study population (incidence rate ratio 0.97, P=0.098); a benefit appeared only in a per-protocol subgroup of children who completed the protocol, which is a weaker form of evidence [Kumpu 2012 PMID 22692023]. A related analysis found LGG did not significantly reduce the detection of respiratory viruses in the nasopharynx, though it was associated with a small reduction in days with respiratory symptoms [Kumpu 2013 PMID 23794458].

The honest summary is that LGG does not appear to reliably prevent or shorten common colds in healthy adults, and even in children the field-trial results are mixed. The benefit is most visible for preventing infections in high-exposure pediatric settings, and even there it is modest.

What About the Cochrane Reviews on Probiotics and Colds?

You may have seen headlines that "probiotics reduce colds." Those come largely from Cochrane systematic reviews, and they carry an important caveat for anyone evaluating LGG.

The current Cochrane review, updated in 2022, pooled 24 trials with roughly 6,950 participants and concluded that probiotics may reduce the number of people who experience at least one acute upper respiratory tract infection, probably reduce the number who experience three or more infections, and probably reduce antibiotic use, though the certainty of evidence ranged from low to moderate [Zhao 2022 PMID 36001877]. An earlier version reached similar conclusions with lower certainty [Hao 2015 PMID 25927096].

Here is the critical point: these reviews pool many different probiotic strains. The favorable conclusions reflect mixed-strain data, not LGG specifically. It would be misleading to read the Cochrane "probiotics help" headline and assume it transfers cleanly to LGG, because the LGG-specific adult trials, as shown above, are largely null. The most defensible claim is that some probiotic strains, in some populations, may modestly reduce respiratory infection burden, and that the strongest LGG-specific signal is in children in group care.

Safety

LGG has one of the best-characterized safety profiles of any probiotic. In a Phase I trial, 15 healthy older adults aged 66 to 80 took a high dose of LGG (10 billion CFU twice daily) for 28 days with no serious adverse events; the side effects that did occur were mild and gastrointestinal, such as bloating and gas [Hibberd 2014 PMID 25438151]. LGG is widely consumed in foods and supplements with a long track record of tolerability in generally healthy people.

The standard caution applies: people who are severely immunocompromised, critically ill, or have central venous catheters should consult a physician before using any probiotic, because rare cases of probiotic-associated infection have been reported in those specific high-risk groups. For generally healthy adults and children, LGG is well tolerated.

How to Think About LGG for Immune Support

Putting the evidence together, here is a grounded way to frame LGG and respiratory health.

• The strongest LGG respiratory evidence is in children in daycare or hospital settings, where it modestly reduces upper respiratory infections and their duration [Hojsak 2010 PMID 19896252; Hojsak 2010 PMID 20403940; Hatakka 2001 PMID 11387176].
• In healthy adults, LGG has not reliably prevented or shortened common colds in controlled trials [Kumpu 2015 PMID 26322544; Tapiovaara 2016 PMID 26990147].
• The "probiotics reduce colds" conclusion from Cochrane reflects mixed strains, not LGG specifically [Zhao 2022 PMID 36001877].
• LGG has a strong safety and tolerability record in healthy people [Hibberd 2014 PMID 25438151].
• The mechanism, immune modulation via the gut, is biologically plausible and supported by lab and animal work, but that is not the same as proven respiratory protection in adults [Ludwig 2018 PMID 30042761; Harata 2010 PMID 20438620].

The most honest positioning for LGG is as a well-studied, well-tolerated daily gut and immune-support strain with its clearest respiratory benefit in children in high-exposure settings, used alongside, not instead of, the basics that actually drive respiratory health: vaccination where appropriate, sleep, hand hygiene, and not smoking.

Dosing and the Wise Choice LGG Product

The trials above used doses generally in the range of 1 to 20 billion CFU per day. Wise Choice Supplements LGG provides 30 billion CFU of Lactobacillus rhamnosus GG per capsule in delayed-release capsules designed to help the strain survive stomach acid and reach the gut, with 90 capsules per bottle for a three-month supply at one capsule daily.

LGG is taken once daily, with or without food. For gut and immune support, consistency over weeks to months matters more than any single dose, since the strain is transient and needs regular intake to maintain colonization-level presence in the gut. You can order Wise Choice Supplements LGG Probiotic as a single-strain, 30-billion-CFU supplement.

What the Evidence Does Not Say

To stay honest about the limits:

• LGG is not a treatment for any respiratory infection, and it does not replace vaccination, medical care, or proven hygiene measures.
• The adult common-cold evidence for LGG is largely null. Anyone claiming LGG prevents colds in healthy adults is going beyond the data.
• The pediatric benefits, while real, are modest reductions in infection frequency and duration, not prevention of all illness.
• Probiotic effects are strain-specific. Evidence for LGG does not automatically apply to other Lactobacillus strains, and mixed-strain review data does not automatically apply to LGG.

Bottom Line

LGG is the most-studied probiotic strain in existence, and its respiratory evidence is a case study in reading research honestly. In children in daycare and hospitals, LGG modestly reduces upper respiratory infections and their duration, a real and useful effect. In healthy adults, the controlled-trial evidence for preventing or shortening colds is largely null. The favorable Cochrane conclusions reflect probiotics as a class, not LGG alone.

As a daily supplement, LGG is well studied and well tolerated, with a plausible immune-modulating mechanism and its clearest respiratory payoff in high-exposure pediatric settings. Wise Choice Supplements LGG delivers a single, named strain at 30 billion CFU in a delayed-release capsule, for people who want the most-researched probiotic strain backed by an honest account of what it can and cannot do.

References

1. Ludwig IS, et al. Lactobacillus rhamnosus GG-derived soluble mediators modulate adaptive immune cells. Frontiers in Immunology. 2018. PMID 30042761.
2. Harata G, et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Letters in Applied Microbiology. 2010. PMID 20438620.
3. Hatakka K, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001. PMID 11387176.
4. Hojsak I, et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition. 2010. PMID 19896252.
5. Hojsak I, et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections in hospitalized children. Pediatrics. 2010. PMID 20403940.
6. Luoto R, et al. Prebiotic and probiotic supplementation and the risk of virus-associated respiratory tract infections in preterm infants. Journal of Allergy and Clinical Immunology. 2014. PMID 24131826.
7. Kumpu M, et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition. 2012. PMID 22692023.
8. Kumpu M, et al. The use of the probiotic Lactobacillus rhamnosus GG and viral findings in the nasopharynx of children attending day care. Journal of Medical Virology. 2013. PMID 23794458.
9. Kumpu M, et al. Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo controlled pilot trial. Beneficial Microbes. 2015. PMID 26322544.
10. Tapiovaara L, et al. Lactobacillus rhamnosus GG in the middle ear and nasopharynx during experimental rhinovirus infection. International Forum of Allergy & Rhinology. 2016. PMID 26990147.
11. Zhao Y, Dong BR, Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews. 2022. PMID 36001877.
12. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews. 2015. PMID 25927096.
13. Hibberd PL, et al. A placebo-controlled phase I/II clinical trial to evaluate the safety and tolerability of Lactobacillus rhamnosus GG in healthy older adults. PLoS One. 2014. PMID 25438151.